" class="no-js "lang="en-US"> Science 37 and NuvoAir Partner to Bring Patient-Centric Experience to Respiratory Clinical Trials - Medtech Alert
Sunday, February 05, 2023

Science 37 and NuvoAir Partner to Bring Patient-Centric Experience to Respiratory Clinical Trials

Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating System™, today announced a partnership with leading digital health company, NuvoAir, to incorporate remote collection of respiratory endpoints data into clinical trial designs—helping to bypass the need for patients to visit hospital sites for lung function testing and other respiratory assessments.

NuvoAir’s clinical trial solution enables the collection and integration of multiple endpoints which are captured from the comfort of patients’ homes via a suite of connected devices (spirometer, inhaler sensor, pulse oximeter, activity tracker and nighttime cough tracker); an integrated patient app; clinician software; and a wrap-around clinical service. This solution facilitates the deployment of agile (hybrid) and fully decentralized clinical trials unlocking many of the potential benefits of agile trials, such as universal access for patients and providers, accelerated enrollment, better retention rates and increased diversity of trial enrollees.

“Strengthening our network of connected devices with NuvoAir reinforces our Agile Clinical Trial Operating System,” said David Coman, Chief Executive Officer, Science 37. “By introducing remote spirometry to patients’ homes, we are significantly reducing patient burden for respiratory trials, while continuing our objective to open up participation beyond the geographic limitations of brick-and-mortar sites.”

Science 37 has seen up to 21x faster patient enrollment, 28% better patient retention, and 3x more diversity from the use of agile and fully decentralized models versus traditional clinical trials. In a recent study, NuvoAir reported that 73% of participating study sites said its solution had a significant positive impact on participants’ willingness to enroll, and over 75% reported a good or excellent impact on retention. There are 3,781 active respiratory clinical trials, with an average enrollment of 2,556 participants, according to data from Evaluate Pharma.

“We are delighted to partner with Science 37 to usher in new patient-centric standards for respiratory trials, internationally,” says Lorenzo Consoli, CEO and Founder of NuvoAir. “This partnership will open the door for more respiratory studies to improve the trial experience for both patients and study sites, and enable important new treatments to reach patients sooner.”

People In This Post

Companies In This Post

  1. Treadwell Therapeutics Announces the Appointment of Roger Sidhu, M.D., as Chief Medical Officer Read more
  2. Personalis and Moderna Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials Read more
  3. Trelleborg to Expand its BioPharmaceutical Manufacturing Footprint in Europe Read more
  4. Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development of MDMA Transdermal Patch Read more
  5. Accenture Expands Strategy Capabilities in Life Sciences with the Acquisition of Bionest Read more